Analysis of urinary metabolites for breast cancer patients receiving chemotherapy by CE-MS coupled with on-line concentration

Clinical Biochemistry

Volumn 46, Issue 12, 2013, Pages 1065-1073

  Yu, Lanfang ^a   Jiang, Cheng ^a   Huang, Sui ^a   Gong, Xingchu ^a   Wang, Shufang ^a   Shen, Peng ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Amino acid; Breast cancer; CE MS; Organic acid; Urine

Indexed keywords

CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; HEXADIMETHRINE BROMIDE; NAVELBINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CAPILLARY ELECTROPHORESIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MASS SPECTROMETRY; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; TREATMENT RESPONSE; URINALYSIS; URINE PH;

AMINO ACID; BREAST CANCER; CE-MS; ORGANIC ACID; URINE;

ADULT; AGED; AMINO ACIDS; BREAST NEOPLASMS; CARBOXYLIC ACIDS; DISCRIMINANT ANALYSIS; ELECTROPHORESIS, CAPILLARY; FEMALE; HEXADIMETHRINE BROMIDE; HUMANS; LEAST-SQUARES ANALYSIS; MASS SPECTROMETRY; METABOLOME; MIDDLE AGED; ONLINE SYSTEMS; PRINCIPAL COMPONENT ANALYSIS; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SOLUTIONS;

EID: 84880796890     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2013.05.049     Document Type: Article

References (44)

1. Fan L., Zheng Y., Yu K.D., Liu G.Y., Wu J., Lu J.S., et al. Breast cancer in a transitional society over 18years: trends and present status in Shanghai, China. Breast Cancer Res Treat 2009, 117:409-416.
2. Al-Naggar RA, Bobryshev YV., Practice and barriers of mammography among Malaysian women in the general population. Asian Pac J Cancer Prev 2012, 13:3595-3600.
3. Takuwa H., Ueno T., Ishiguro H., Mikami Y., Kanao S., Takada M., et al. A case of metaplastic breast cancer that showed a good response to platinum-based preoperative chemotherapy. Breast Cancer 2011, 1-4.
4. Watanabe T., Sano M., Takashima S., Kitaya T., Tokuda Y., Yoshimoto M., et al. Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial. J Clin Oncol 2009, 27:1368-1374.
5. Fisher C.S., Ma C.X., Gillanders W.E., Aft R.L., Eberlein T.J., Gao F., et al. Neoadjuvant chemotherapy is associated with improved survival compared with adjuvant chemotherapy in patients with triple-negative breast cancer only after complete pathologic response. Ann Surg Oncol 2012, 19:253-258.
6. Sinagra D., Amato C., Scarpilta A.M., Brigandi M., Amato M., Saura G., et al. Metabolic syndrome and breast cancer risk. Eur Rev Med Pharmacol Sci 2002, 6:55-59.
7. Wei S., Liu L., Zhang J., Bowers J., Gowda G., Seeger H., et al. Metabolomics approach for predicting response to neoadjuvant chemotherapy for breast cancer. Mol Oncol 2013, 7:297-307.
8. Manoharan A., Chen C.F., Wilson L.S., Griffiths K.A., Robinson D.E. Ultrasonic characterization of splenic tissue in myelofibrosis: further evidence for reversal of fibrosis with chemotherapy. Eur J Haematol 2009, 40:149-154.
9. Duch J., Fuster D., Muñoz M., Fernández P.L., Paredes P., Fontanillas M., et al. 18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer. Eur J Nucl Med Mol Imaging 2009, 36:1551-1557.
10. Tagami T., Foltz W.D., Ernsting M.J., Lee C.M., Tannock I.F., May J.P., et al. MRI monitoring of intratumoral drug delivery and prediction of the therapeutic effect with a multifunctional thermosensitive liposome. Biomaterials 2011, 32:6570-6578.
11. 1H magnetic resonance spectroscopy with diffusion magnetic resonance imaging. Jpn J Radiol 2010, 28:101-109.
12. Cristofanilli M., Budd G.T., Ellis M.J., Stopeck A., Matera J., Miller M.C., et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004, 351:781-791.
13. Ng D.J.Y., Pasikanti K.K., Chan E.C.Y. Trend analysis of metabonomics and systematic review of metabonomics-derived cancer marker metabolites. Metabolomics 2011, 7:155-178.
14. Kubota A., Meguid M.M., Hitch D.C. Amino acid profiles correlate diagnostically with organ site in three kinds of malignant tumors. Cancer 1992, 69:2343-2348.
15. Sugimoto M., Wong D.T., Hirayama A., Soga T., Tomita M. Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles. Metabolomics 2010, 6:78-95.
16. Xie G.X., Chen T.L., Qiu Y.P., Shi P., Zheng X.J., Su M.M., et al. Urine metabolite profiling offers potential early diagnosis of oral cancer. Metabolomics 2012, 8:220-231.
17. Chen T., Xie G., Wang X., Fan J., Qiu Y., Zheng X., et al. Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma. Mol Cell Proteomics 2011, 10.
18. Chen Y., Zhang R., Song Y., He J., Sun J., Bai J., et al. RRLC-MS/MS-based metabonomics combined with in-depth analysis of metabolic correlation network: finding potential biomarkers for breast cancer. Analyst 2009, 134:2003-2011.
19. Henneges C., Bullinger D., Fux R., Friese N., Seeger H., Neubauer H., et al. Prediction of breast cancer by profiling of urinary RNA metabolites using support vector machine-based feature selection. BMC Cancer 2009, 9:104.
20. Sitter B., Bathen T.F., Singstad T.E., Fjøsne H.E., Lundgren S., Halgunset J., et al. Quantification of metabolites in breast cancer patients with different clinical prognosis using HR MAS MR spectroscopy. NMR Biomed 2010, 23:424-431.
21. Ching N., Grossi C., Jham G., Angers J., Zurawinsky H., Ching C., et al. Plasma amino acid and serum unesterified fatty acid deficits and the effect of nutritional support in chemotherapy treatment. Surgery 1984, 95:730.
22. Ichikawa M., Kobayashi R., Nakajima M., Inamoto J., Suzuki D., Cho Y., et al. Higher urinary excretion of inorganic phosphate during early induction chemotherapy predicts a good prognosis in childhood acute leukemia. J Pediatr Hematol Oncol 2011, 33:e143.
23. Schiffer E., Mischak H., Novak J. High resolution proteome/peptidome analysis of body fluids by capillary electrophoresis coupled with MS. Proteomics 2006, 6:5615-5627.
24. Wang S., Yang P., Zhao X. Amino acid profile determination in the urine of bladder cancer patients by CE-MS with on-line pH-mediated stacking and pattern recognition. Chromatographia 2009, 70:1479-1484.
25. Egner J.R. AJCC cancer staging manual. JAMA 2010, 304:1726-1727.
26. Wang S.F., Yang P., Zhao X.P. Amino acid profile determination in the urine of bladder cancer patients by CE-MS with on-line pH-mediated stacking and pattern recognition. Chromatographia 2009, 70:1479-1484.
27. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92:205-216.
28. Pavlides S., Tsirigos A., Migneco G., Whitaker-Menezes D., Chiavarina B., Flomenberg N., et al. The autophagic tumor stroma model of cancer: role of oxidative stress and ketone production in fueling tumor cell metabolism. Cell Cycle 2010, 9:3485-3505.
29. Slupsky C.M., Steed H., Wells T.H., Dabbs K., Schepansky A., Capstick V., et al. Urine metabolite analysis offers potential early diagnosis of ovarian and breast cancers. Clin Cancer Res 2010, 16:5835-5841.
30. Garber K. Energy boost: the Warburg effect returns in a new theory of cancer. J Natl Cancer Inst 2004, 96:1805-1806.
31. Garcia E., Andrews C., Hua J., Kim H.L., Sukumaran D.K., Szyperski T., et al. Diagnosis of early stage ovarian cancer by 1H NMR metabonomics of serum explored by use of a microflow NMR probe. J Proteome Res 2011, 10:1765-1771.
32. Icard P., Poulain L., Lincet H. Understanding the central role of citrate in the metabolism of cancer cells. Biochim. Biophys. Acta (BBA)-Rev. Cancer 2012, 1825:111-116.
33. Mullen A.R., DeBerardinis R.J. Genetically-defined metabolic reprogramming in cancer. Trends Endocrinol Metab 2012, 23:552-559.
34. 1H MRS at 1.5Tesla confirmed by ex-vivo high-resolution magic-angle spinning NMR. NMR Biomed 2010, 23:80-87.
35. Moestue S.A., Borgan E., Huuse E.M., Lindholm E.M., Sitter B., Børresen-Dale A.L., et al. Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models. BMC Cancer 2010, 10:433.
36. Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L., et al. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science 2012, 336:1040-1044.
37. Cao M.D., Giskeødegård G.F., Bathen T.F., Sitter B., Bofin A., Lønning P.E., et al. Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy. BMC Cancer 2012, 12:39.
38. Peeling J., Sutherland G. High-resolution 1H NMR spectroscopy studies of extracts of human cerebral neoplasms. Magn Reson Med 1992, 24:123-136.
39. Farwick M., Siewe R., Krämer R. Glycine betaine uptake after hyperosmotic shift in Corynebacterium glutamicum. J Bacteriol 1995, 177:4690-4695.
40. Mikalauskas S., Mikalauskiene L., Bruns H., Nickkholgh A., Hoffmann K., Longerich T., et al. Dietary glycine protects from chemotherapy-induced hepatotoxicity. Amino Acids 2011, 40:1139-1150.
41. Scioscia K.A., Snyderman C.H., Wagner R. Altered serum amino acid profiles in head and neck. Nutr Cancer 1998, 30:144-147.
42. Platten M., Weller M., Wick W. Shaping the glioma immune microenvironment through tryptophan metabolism. CNS Oncol 2012, 1:99-106.
43. Platten M., Wick W., Van den Eynde B.J. Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. Cancer Res 2012, 72:5435-5440.
44. Greenhaff P., Bodin K., Soderlund K., Hultman E. Effect of oral creatine supplementation on skeletal muscle phosphocreatine resynthesis. Am J Physiol Endocrinol Metab 1994, 266:E725-E730.